Open Access

Ribozyme targeting

  • Jonathan B Weitzman
Genome Biology20023:spotlight-20020321-01

https://doi.org/10.1186/gb-spotlight-20020321-01

Published: 21 March 2002

In the March 19 Proceedings of the National Academy of Sciences, Kashani-Sabet et al. describe the use of plasmid-based ribozymes as functional genomics tools to unravel complex phenotypes, such as cancer metastasis (Proc Natl Acad Sci USA 2002, 99:3878-3883). They reasoned that ribozyme-based gene targeting in mice might overcome experimental problems associated with transgenesis and lethal knockout phenotypes. They tested the use of systemic administration of cationic liposome:DNA complexes (CLDCs) to express hammerhead ribozymes in tumour-bearing mice; they targeted the p65 and p50 subunits of the NF-kappaB transcription factor using expression plasmids based on Epstein-Barr virus and including 35-bp ribozymes. They injected the CLDCs into the bloodstream of mice and noted a reduction in NF-κB proteins in metastatic tumour cells. The ribozymes affected the metastatic spread of melanoma cells; and the ribozymes appear to be more effective than antisense strategies, offering an experimental strategy to dissect complex traits in adult animals.

References

  1. Proceedings of the National Academy of Sciences, [http://www.pnas.org]
  2. Activators and target genes of Rel/NF-kB transcription factors.Google Scholar
  3. The experimental use of antisense oligonucleotides: a guide for the perplexed.Google Scholar

Copyright

© BioMed Central Ltd 2002

Advertisement